Drug Profile
Personalised LADD immunotherapy - Chinook Therapeutics
Alternative Names: pLADDLatest Information Update: 18 Aug 2023
Price :
$50
*
At a glance
- Originator Aduro BioTech
- Class Antineoplastics; Attenuated vaccines; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 11 Aug 2023 Chinook Therapeutics has been acquired by Novartis
- 28 Oct 2022 No recent reports of development identified for phase-I development in Colorectal-cancer(Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 05 Oct 2020 Aduro Biotech has been merged with Chinook Therapeutics to form Chinook Therapeutics